Wilms' tumor gene expression by normal and malignant human B lymphocytes

P. Spinsanti, U. De Grazia, A. Faggioni, L. Frati, A. Calogero, G. Ragona

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Very little is known about Wilms' tumor gene (WT1) expression in B cells and its importance for growth regulation and differentiation. We have investigated WT1 expression in fresh B lymphocytes and in a panel of B-cell lines of normal and malignant origin, including both Epstein-Barr virus (EBV) genome negative and EBV carrying cell lines. WT1 is constitutively activated in all lymphoblastoid cell lines (LCL) derived from EBV immortalization of lymphocytes from normal donors in vitro. These cell lines are distinguished for the presence of activated B-cell markers and an unrestricted expression of viral latent genes. In contrast, WT1 expression is abrogated in normal B lymphocytes and in all Burkitt tumor derived cell lines, irrespective of the EBV genome carrying status and their phenotype pattern. A single step RT-PCR for simultaneous detection of the four spliced transcript isoforms has been applied to confirm their expression. Analysis of variant relative proportions suggested the maintenance of a balanced expression of the isoforms in LCL, as reported in non tumorous tissues. These data, together with the evidence that the replication in vitro of lymphoblastoid cells is not affected by WT1 activation following viral immortalization, support the hypothesis that gene inactivation, in addition to disrupted alternate splicing, may play a role in growth control derangements.

Original languageEnglish
Pages (from-to)611-619
Number of pages9
JournalLeukemia and Lymphoma
Volume38
Issue number5-6
Publication statusPublished - 2000

Fingerprint

Wilms' Tumor Genes
B-Lymphocytes
Human Herpesvirus 4
Gene Expression
Cell Line
Protein Isoforms
Genome
Virus Activation
Burkitt Lymphoma
Viral Genes
Alternative Splicing
Gene Silencing
Growth
Tumor Cell Line
Maintenance
Lymphocytes
Phenotype
Polymerase Chain Reaction

Keywords

  • B lymphocytes
  • BLs
  • EBV
  • LCL
  • WT1

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Spinsanti, P., De Grazia, U., Faggioni, A., Frati, L., Calogero, A., & Ragona, G. (2000). Wilms' tumor gene expression by normal and malignant human B lymphocytes. Leukemia and Lymphoma, 38(5-6), 611-619.

Wilms' tumor gene expression by normal and malignant human B lymphocytes. / Spinsanti, P.; De Grazia, U.; Faggioni, A.; Frati, L.; Calogero, A.; Ragona, G.

In: Leukemia and Lymphoma, Vol. 38, No. 5-6, 2000, p. 611-619.

Research output: Contribution to journalArticle

Spinsanti, P, De Grazia, U, Faggioni, A, Frati, L, Calogero, A & Ragona, G 2000, 'Wilms' tumor gene expression by normal and malignant human B lymphocytes', Leukemia and Lymphoma, vol. 38, no. 5-6, pp. 611-619.
Spinsanti, P. ; De Grazia, U. ; Faggioni, A. ; Frati, L. ; Calogero, A. ; Ragona, G. / Wilms' tumor gene expression by normal and malignant human B lymphocytes. In: Leukemia and Lymphoma. 2000 ; Vol. 38, No. 5-6. pp. 611-619.
@article{33f014cc24b94722a86c12e7488a8717,
title = "Wilms' tumor gene expression by normal and malignant human B lymphocytes",
abstract = "Very little is known about Wilms' tumor gene (WT1) expression in B cells and its importance for growth regulation and differentiation. We have investigated WT1 expression in fresh B lymphocytes and in a panel of B-cell lines of normal and malignant origin, including both Epstein-Barr virus (EBV) genome negative and EBV carrying cell lines. WT1 is constitutively activated in all lymphoblastoid cell lines (LCL) derived from EBV immortalization of lymphocytes from normal donors in vitro. These cell lines are distinguished for the presence of activated B-cell markers and an unrestricted expression of viral latent genes. In contrast, WT1 expression is abrogated in normal B lymphocytes and in all Burkitt tumor derived cell lines, irrespective of the EBV genome carrying status and their phenotype pattern. A single step RT-PCR for simultaneous detection of the four spliced transcript isoforms has been applied to confirm their expression. Analysis of variant relative proportions suggested the maintenance of a balanced expression of the isoforms in LCL, as reported in non tumorous tissues. These data, together with the evidence that the replication in vitro of lymphoblastoid cells is not affected by WT1 activation following viral immortalization, support the hypothesis that gene inactivation, in addition to disrupted alternate splicing, may play a role in growth control derangements.",
keywords = "B lymphocytes, BLs, EBV, LCL, WT1",
author = "P. Spinsanti and {De Grazia}, U. and A. Faggioni and L. Frati and A. Calogero and G. Ragona",
year = "2000",
language = "English",
volume = "38",
pages = "611--619",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Taylor and Francis Ltd.",
number = "5-6",

}

TY - JOUR

T1 - Wilms' tumor gene expression by normal and malignant human B lymphocytes

AU - Spinsanti, P.

AU - De Grazia, U.

AU - Faggioni, A.

AU - Frati, L.

AU - Calogero, A.

AU - Ragona, G.

PY - 2000

Y1 - 2000

N2 - Very little is known about Wilms' tumor gene (WT1) expression in B cells and its importance for growth regulation and differentiation. We have investigated WT1 expression in fresh B lymphocytes and in a panel of B-cell lines of normal and malignant origin, including both Epstein-Barr virus (EBV) genome negative and EBV carrying cell lines. WT1 is constitutively activated in all lymphoblastoid cell lines (LCL) derived from EBV immortalization of lymphocytes from normal donors in vitro. These cell lines are distinguished for the presence of activated B-cell markers and an unrestricted expression of viral latent genes. In contrast, WT1 expression is abrogated in normal B lymphocytes and in all Burkitt tumor derived cell lines, irrespective of the EBV genome carrying status and their phenotype pattern. A single step RT-PCR for simultaneous detection of the four spliced transcript isoforms has been applied to confirm their expression. Analysis of variant relative proportions suggested the maintenance of a balanced expression of the isoforms in LCL, as reported in non tumorous tissues. These data, together with the evidence that the replication in vitro of lymphoblastoid cells is not affected by WT1 activation following viral immortalization, support the hypothesis that gene inactivation, in addition to disrupted alternate splicing, may play a role in growth control derangements.

AB - Very little is known about Wilms' tumor gene (WT1) expression in B cells and its importance for growth regulation and differentiation. We have investigated WT1 expression in fresh B lymphocytes and in a panel of B-cell lines of normal and malignant origin, including both Epstein-Barr virus (EBV) genome negative and EBV carrying cell lines. WT1 is constitutively activated in all lymphoblastoid cell lines (LCL) derived from EBV immortalization of lymphocytes from normal donors in vitro. These cell lines are distinguished for the presence of activated B-cell markers and an unrestricted expression of viral latent genes. In contrast, WT1 expression is abrogated in normal B lymphocytes and in all Burkitt tumor derived cell lines, irrespective of the EBV genome carrying status and their phenotype pattern. A single step RT-PCR for simultaneous detection of the four spliced transcript isoforms has been applied to confirm their expression. Analysis of variant relative proportions suggested the maintenance of a balanced expression of the isoforms in LCL, as reported in non tumorous tissues. These data, together with the evidence that the replication in vitro of lymphoblastoid cells is not affected by WT1 activation following viral immortalization, support the hypothesis that gene inactivation, in addition to disrupted alternate splicing, may play a role in growth control derangements.

KW - B lymphocytes

KW - BLs

KW - EBV

KW - LCL

KW - WT1

UR - http://www.scopus.com/inward/record.url?scp=0033867009&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033867009&partnerID=8YFLogxK

M3 - Article

C2 - 10953983

AN - SCOPUS:0033867009

VL - 38

SP - 611

EP - 619

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 5-6

ER -